Development of Target Delivery System Based on Actinomycin Class Drugs and Recombinant Alpha-fetoprotein
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
A recombinant alpha-fetoprotein (rAFP) was obtained in the yeast P. pastoris system, and its functional activity was confirmed. A method for producing polymer particles loaded with dactinomycin was developed, and a conjugate of these nanoparticles with rAFP was synthesized. The efficiency of the obtained conjugate on the HeLa, SKOV3, and MG-63 tumor cells and the absence of toxicity on the normal cells was shown. Experiments in vivo demonstrated a significant increase in the antitumor efficacy of the conjugate at a lower general toxicity as compared to the commercially available dactinomycin.
References
1.
Posypanova G, Gorokhovets N, Makarov V, Savvateeva L, Kireeva N, Severin S
. Recombinant alpha-fetoprotein C-terminal fragment: the new recombinant vector for targeted delivery. J Drug Target. 2008; 16(4):321-8.
DOI: 10.1080/10611860801927721.
View
2.
Severin S, Moskaleva EYu , Shmyrev I, Posypanova G, Belousova YuV , Sologub V
. Alpha-fetoprotein-mediated targeting of anti-cancer drugs to tumor cells in vitro. Biochem Mol Biol Int. 1995; 37(2):385-92.
View